A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

May 6, 2022

Study Completion Date

July 12, 2022

Conditions

Healthy

Interventions

DRUG

Milvexian

Milvexian will be administered orally or via nasogastric route as tablets or capsules.

Trial Locations (1)

PRA Health Sciences, Salt Lake City

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY